<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250951</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670ARU01</org_study_id>
    <nct_id>NCT01250951</nct_id>
  </id_info>
  <brief_title>This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.</brief_title>
  <official_title>1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of deferasirox in patients with MDS,
      thalassemia and rare anemia patients with transfusion iron overload.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in ferritin level, compared to baseline, in patients with transfusion-induced iron overload treated with Exjade</measure>
    <time_frame>Baseline assessment is followed by monthly assessments for up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in clinical manifestations of iron overload by means of echocardiogram (ECHO), electrocardiogram (ECG), routine laboratory assessments and physical examination</measure>
    <time_frame>Baseline assessment is followed by monthly assessments for up to 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in iron overload evidence on cardiac and liver magnetic resonance imaging (MRI) T2*, compared to baseline, in patients with transfusion-induced iron overload treated with Exjade</measure>
    <time_frame>at baseline and 1 at year (at the end of study).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events. Safety is evaluated through the continuous monitoring and recording of adverse events, as well as though routine laboratory assessments and physical examination.</measure>
    <time_frame>From the start of study up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Deferasirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <arm_group_label>Deferasirox</arm_group_label>
    <other_name>ICL670</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 2 years

          2. Primary Diagnosis: Myelodysplastic Syndrome (presenting with low or intermediate-1
             IPSS risk), thalassemia or rare anemias patients (anemia Diamond-Blackfan, Fanconi's
             anemia, Sideroblastic anemia, Red cell aplasia)

          3. ECOG Performance Status ≤ 2

          4. Transfusion overload confirmed with ferritin level &gt;1000 µg/l.

          5. No severe concomitant uncontrolled disease (uncontrolled diabetes mellitus, heart
             failure, renal failure).

          6. Serum creatine level &gt; ULN

          7. No proteinuria

          8. Liver enzymes level &lt; 5 ULN.

          9. No pregnancy or lactation

         10. Signed informed consent by adults. In case inclusion of children under 18 years old,
             the informed consent should be signed by parents.

        Exclusion Criteria:

          1. Age &lt; 2 years

          2. No iron overload (Ferritin level &lt;1000 µg/l).

          3. Primary iron overload (hereditary hemochromatosis)

          4. Severe concomitant disease (uncontrolled diabetes mellitus, heart failure, renal
             failure)

          5. Elevated serum creatinine &gt; ULN or/and proteinuria

          6. Liver enzymes level &gt;5 ULN.

          7. Pregnancy or lactation.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/druginfo/meds/a606002.html</url>
    <description>Deferasirox</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/thalassemia.html</url>
    <description>Thalassemia</description>
  </link>
  <link>
    <url>http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3aproject=medlineplus&amp;v%3asources=medlineplus-bundle&amp;query=myelodysplastic%20syndrome&amp;</url>
    <description>Myelodisplastic Syndrome</description>
  </link>
  <link>
    <url>http://www.irondisorders.org/Websites/idi/Images/TIOtrifold.pdf</url>
    <description>Transfusional Iron Overload</description>
  </link>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=7524</url>
    <description>Results for CICL670ARU01 on the Novartis Clinical Trial Results Website</description>
  </link>
  <link>
    <url>http://elibrary.ru/item.asp?id=24872220.</url>
  </link>
  <results_reference>
    <citation>Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010 Apr;95(4):557-66. doi: 10.3324/haematol.2009.014696. Epub 2009 Nov 30.</citation>
    <PMID>19951979</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron Overload</keyword>
  <keyword>hemotranfusion</keyword>
  <keyword>deferasirox</keyword>
  <keyword>ferritin</keyword>
  <keyword>Rare anemia</keyword>
  <keyword>Transfusional Iron Overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

